ACLARION, INC. (ACON) Current Ratio
- Current ratio · latest quarter: Value 16.20×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 16.20× | Current assets / current liabilities. $16.79M ÷ $1.04M ≈ 16.20× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 16.79M USD | Assets, Current |
| Current obligations | 1.04M USD | Liabilities, Current |
| Cash and equivalents | 16.29M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 28.17K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 704.98K USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $16.79M | $1.04M | $16.29M | (m) | $28.17K | (m) | $704.98K | (m) | 16.20× |
| 2026-03-31 | $19.38M | $986.21K | $19.00M | (m) | $40.58K | (m) | $587.29K | (m) | 19.65× |
| 2025-12-31 | $12.40M | $837.29K | $12.02M | (m) | $29.68K | (m) | $332.96K | (m) | 14.81× |
| 2025-09-30 | $11.90M | $699.75K | $11.34M | (m) | $32.02K | (m) | $274.36K | (m) | 17.01× |
| 2025-06-30 | $13.44M | $564.42K | $12.83M | (m) | $20.92K | (m) | $281.52K | (m) | 23.81× |
| 2025-03-31 | $15.16M | $699.03K | $14.75M | (m) | $19.17K | (m) | $516.27K | (m) | 21.68× |
| 2024-12-31 | $824.28K | $1.15M | $453.66K | (m) | $18.33K | (m) | $531.60K | (m) | 0.71× |
| 2024-09-30 | $1.90M | $678.27K | $1.31M | (m) | $16.95K | (m) | $331.76K | (m) | 2.80× |
| 2024-06-30 | $1.85M | $1.45M | $1.17M | (m) | $19.71K | (m) | $179.12K | (m) | 1.28× |
| 2024-03-31 | $2.54M | $1.22M | $2.13M | (m) | $17.21K | (m) | $195.71K | (m) | 2.08× |
| 2023-12-31 | $1.29M | $3.19M | $1.02M | (m) | $13.27K | (m) | $760.53K | (m) | 0.40× |
| 2023-09-30 | $364.95K | $2.37M | (m) | (m) | $21.19K | (m) | $686.20K | (m) | 0.15× |
| 2023-06-30 | $798.09K | $1.99M | (m) | (m) | $10.37K | (m) | $607.62K | (m) | 0.40× |
| 2023-03-31 | $675.53K | $736.41K | (m) | (m) | $17.15K | (m) | $544.74K | (m) | 0.92× |
| 2022-12-31 | $1.70M | $688.67K | $1.47M | (m) | $18.57K | (m) | $462.20K | (m) | 2.47× |
| 2021-12-31 | $732.20K | $7.62M | $432.53K | (m) | $6.28K | (m) | $1.07M | (m) | 0.10× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |